Takeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced supportive phase 2a trial data. Gastrointestinal diseases are one of the Japanese ...

This repository provides unofficial binary wheels for Pygame for Python on Windows. The files are unofficial (meaning: informal, unrecognized, personal, unsupported, no warranty, no liability, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

If you want a more in-depth explanation/tutorial on virtual environments in Python, I'd highly suggest the videos made by Corey Schafer: Windows: Python Tutorial: VENV (Windows) - How to Use Virtual ...

COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission with a series A raise. It took COUR Pharmaceuticals a full decade before ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Have you ever wished you could generate interactive websites with HTML, CSS, and JavaScript while programming in nothing but Python? Here are three frameworks that do the trick. Python has long had a ...

Ewan has been a content writer since 2020, and loves nothing more than discussing all things gaming. While he's been playing games all his life, he has a particular interesting in anything even ...

CNP-104 is a biodegradable nanoparticle that previously received fast track designation from FDA in January 2022, which would eventually make it eligible for accelerated approval and priority review.

Cour Pharmaceuticals, a local biotech startup that’s raised north of $100 million from investors, has inked a new licensing deal with a Roche subsidiary that’s valued at more than $900 million. The ...

Chicago’s Cour Pharmaceuticals—recently honored as one of Fierce Biotech’s 2024 Fierce 15—is bringing its immunology mission to the fore with a new deal featuring Swiss drug juggernaut Roche. Roche’s ...

During a busy day of dealmaking, Cour Pharmaceutical Development Co. Inc. entered a pact with Roche Holding AG’s Genentech unit to advance tolerogenic nanoparticle treatments for an autoimmune disease ...